Hungarian pharmaceutical company Gedeon Richter announced on Tuesday the acquisition of the women's health discovery portfolio of US-based biotech company Celmatix.
The portfolio includes assets targeting fertility, endometriosis and ovarian ageing. The development of the acquired programmes will be led by Richter's women's health R+D hub in Belgium.
Celmatix will receive an upfront payment and will be eligible to receive development milestone payments as the drug pipeline advances into clinic and registration phase.
Top 5 Articles
Duna House Profit Climbs Nearly 70% in Q3 November 24, 2025 
'Recharge' Campaign Launched to Boost Domestic Tourism January 21, 2026 
What Awaits the Hungarian Economy in 2026 and 2027? April 24, 2026 
Richter Earnings Slip as Financial Loss Weighs November 6, 2025 
Genius Automotive Hungarian Subsidiary's CEE Expansion November 2, 2025
